JP7522720B2 - アゾロピリミジン化合物の固体形態 - Google Patents

アゾロピリミジン化合物の固体形態 Download PDF

Info

Publication number
JP7522720B2
JP7522720B2 JP2021502476A JP2021502476A JP7522720B2 JP 7522720 B2 JP7522720 B2 JP 7522720B2 JP 2021502476 A JP2021502476 A JP 2021502476A JP 2021502476 A JP2021502476 A JP 2021502476A JP 7522720 B2 JP7522720 B2 JP 7522720B2
Authority
JP
Japan
Prior art keywords
cancer
compound
xrpd
solid form
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021502476A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531273A (ja
JPWO2020018680A5 (https=
JP2021531273A5 (https=
Inventor
レイ ジェフリー ジェナ
レディー レレティ マンモハン
ハーディング マイルズ ディロン
パトリック パワーズ ジェイ
Original Assignee
アーカス バイオサイエンシズ インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アーカス バイオサイエンシズ インコーポレイティド filed Critical アーカス バイオサイエンシズ インコーポレイティド
Publication of JP2021531273A publication Critical patent/JP2021531273A/ja
Publication of JPWO2020018680A5 publication Critical patent/JPWO2020018680A5/ja
Publication of JP2021531273A5 publication Critical patent/JP2021531273A5/ja
Priority to JP2024063946A priority Critical patent/JP2024083556A/ja
Application granted granted Critical
Publication of JP7522720B2 publication Critical patent/JP7522720B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2021502476A 2018-07-18 2019-07-17 アゾロピリミジン化合物の固体形態 Active JP7522720B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024063946A JP2024083556A (ja) 2018-07-18 2024-04-11 アゾロピリミジン化合物の固体形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862700064P 2018-07-18 2018-07-18
US62/700,064 2018-07-18
PCT/US2019/042226 WO2020018680A1 (en) 2018-07-18 2019-07-17 Solid forms of an azolopyrimidine compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024063946A Division JP2024083556A (ja) 2018-07-18 2024-04-11 アゾロピリミジン化合物の固体形態

Publications (4)

Publication Number Publication Date
JP2021531273A JP2021531273A (ja) 2021-11-18
JPWO2020018680A5 JPWO2020018680A5 (https=) 2022-07-26
JP2021531273A5 JP2021531273A5 (https=) 2022-07-26
JP7522720B2 true JP7522720B2 (ja) 2024-07-25

Family

ID=69164033

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021502476A Active JP7522720B2 (ja) 2018-07-18 2019-07-17 アゾロピリミジン化合物の固体形態
JP2024063946A Withdrawn JP2024083556A (ja) 2018-07-18 2024-04-11 アゾロピリミジン化合物の固体形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024063946A Withdrawn JP2024083556A (ja) 2018-07-18 2024-04-11 アゾロピリミジン化合物の固体形態

Country Status (12)

Country Link
US (1) US11993584B2 (https=)
EP (1) EP3823614A4 (https=)
JP (2) JP7522720B2 (https=)
KR (1) KR102826213B1 (https=)
CN (1) CN113015523B (https=)
AU (1) AU2019306582B2 (https=)
CA (1) CA3106366A1 (https=)
MY (1) MY205549A (https=)
PH (1) PH12021550084A1 (https=)
SG (1) SG11202100267TA (https=)
TW (1) TWI835821B (https=)
WO (1) WO2020018680A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020185859A1 (en) 2019-03-12 2020-09-17 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
US12310965B2 (en) 2019-03-29 2025-05-27 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
CN119768155A (zh) 2022-09-14 2025-04-04 艾库斯生物科学有限公司 依曲地南的分散体
WO2024097736A1 (en) 2022-11-02 2024-05-10 Arcus Biosciences, Inc. Processes for preparing azolopyrimidine compounds
WO2025193759A1 (en) 2024-03-12 2025-09-18 Gilead Sciences, Inc. Solid forms of an azolopyrimidine compound

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524638A (ja) 2017-01-20 2019-09-05 アーカス バイオサイエンシズ インコーポレイティド 癌関連障害の治療のためのアゾロピリミジン

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474599A (en) 1982-07-14 1984-10-02 The Dow Chemical Company 1-(Pyridyl)-1H-1,2,3-triazole derivatives, and use as herbicidal agents
WO2003051833A2 (en) * 2001-12-18 2003-06-26 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
ES2776406T3 (es) 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
US20110313001A1 (en) 2008-12-16 2011-12-22 Christian Fischer Triazole derivatives for treatment of alzheimer's disease
EP2473531A4 (en) 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr antibodies
PH12012500881A1 (en) 2009-12-10 2017-07-26 Hoffmann La Roche Antibodies binding preferentially human csf1r extracellular domain 4 and their use
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
CA2789076C (en) 2010-03-05 2017-11-21 F. Hoffmann-La Roche Ag Antibodies against human colony stimulating factor-1 receptor and uses thereof
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
MX378336B (es) 2010-05-04 2025-03-10 Five Prime Therapeutics Inc Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
PT2614082T (pt) 2010-09-09 2018-12-03 Pfizer Moléculas de ligação a 4-1bb
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
BR112014012624A2 (pt) 2011-12-15 2018-10-09 F Hoffmann-La Roche Ag anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
RU2014136332A (ru) 2012-02-06 2016-03-27 Дженентек, Инк. Композиции и способы применения ингибиторов csf1r
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP2847220A1 (en) 2012-05-11 2015-03-18 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
EP2900665B1 (en) * 2012-09-28 2018-01-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
HK1222658A1 (zh) * 2013-07-17 2017-07-07 Otsuka Pharmaceutical Co., Ltd. 氰基三唑化合物
CA3090922A1 (en) 2018-02-16 2019-08-22 Arcus Biosciences, Inc. Dosing with an azolopyrimidine compound
WO2020185859A1 (en) 2019-03-12 2020-09-17 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
US12310965B2 (en) 2019-03-29 2025-05-27 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
MY209362A (en) 2019-06-06 2025-07-03 Arcus Biosciences Inc Processes for preparing aminopyrimidine compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524638A (ja) 2017-01-20 2019-09-05 アーカス バイオサイエンシズ インコーポレイティド 癌関連障害の治療のためのアゾロピリミジン

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ファルマシア，2016年，Vol.52, No.5，pp.387-391

Also Published As

Publication number Publication date
EP3823614A4 (en) 2022-03-30
TW202011964A (zh) 2020-04-01
JP2021531273A (ja) 2021-11-18
CA3106366A1 (en) 2020-01-23
EP3823614A1 (en) 2021-05-26
US20210269422A1 (en) 2021-09-02
TWI835821B (zh) 2024-03-21
KR20210033503A (ko) 2021-03-26
JP2024083556A (ja) 2024-06-21
SG11202100267TA (en) 2021-02-25
WO2020018680A1 (en) 2020-01-23
AU2019306582B2 (en) 2023-03-16
CN113015523A (zh) 2021-06-22
US11993584B2 (en) 2024-05-28
AU2019306582A1 (en) 2021-03-11
CN113015523B (zh) 2024-07-16
KR102826213B1 (ko) 2025-06-27
PH12021550084A1 (en) 2021-11-08
MY205549A (en) 2024-10-25

Similar Documents

Publication Publication Date Title
JP7394831B2 (ja) ピリドンａ２ｒアンタゴニスト
JP7665534B2 (ja) ２，３，５－三置換ピラゾロ［１，５－ａ］ピリミジン化合物
TWI789393B (zh) 用於治療癌症相關疾病之喹唑啉-吡啶衍生物
JP7522720B2 (ja) アゾロピリミジン化合物の固体形態
US12281136B2 (en) Crystalline forms of a CD73 inhibitor and uses thereof
US11478479B2 (en) Dosing with an azolopyrimidine compound
HK40052625A (en) Solid forms of an azolopyrimidine compound
HK40052625B (zh) 偶氮嘧啶化合物的固体形式
HK40068316A (en) 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds
HK40054296A (en) Pyridone a2r antagonists
HK40054296B (en) Pyridone a2r antagonists
HK40068316B (zh) 2，3，5-三取代吡唑并[1，5-a]嘧啶化合物
HK40055891B (zh) 吡啶酮a2r拮抗剂
HK40024629B (en) Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
HK40024629A (en) Quinazoline-pyridine derivatives for the treatment of cancer-related disorders

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220527

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220715

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230927

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240411

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240418

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240617

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240712

R150 Certificate of patent or registration of utility model

Ref document number: 7522720

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150